<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>PGHL</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">PGHL</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="procter-gamble-health-limited" class="section level1">
<h1>Procter &amp; Gamble Health Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.PGHL.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.PGHL.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.PGHL.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.PGHL.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.PGHL.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.PGHL.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.PGHL.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.PGHL.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.PGHL.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="pghl-procter-gamble-health-limited-investment-summary-business-analysis" class="section level9">
<p class="heading"><strong>PGHL (Procter &amp; Gamble Health Limited) ‚Äì Investment Summary &amp; Business Analysis</strong></p>
<p><em>(As of November 2025)</em></p>
<p>Based on the provided filings and disclosures, here is a comprehensive analysis of <strong>Procter &amp; Gamble Health Limited (PGHL)</strong>, including its <strong>tailwinds, headwinds, growth prospects, and key risks</strong>, for investors and stakeholders assessing the stock listed on BSE (Scrip Code: 500126) and NSE (Symbol: PGHL).</p>
<hr />
</div>
<div id="company-overview" class="section level6">
<h6>üîç <strong>Company Overview</strong></h6>
<ul>
<li><strong>Industry</strong>: Healthcare ‚Äì Vitamins, Minerals &amp; Supplements (VMS)<br />
</li>
<li><strong>Core Brands</strong>: Neurobion, Livogen, Seven Seas, Evion, Polybion, Nasivion<br />
</li>
<li><strong>Public Listing Status</strong>: Listed on BSE &amp; NSE<br />
</li>
<li><strong>Financial Year Changed</strong>: From June to March (FY ended March 31, 2025 was a <strong>9-month transition year</strong>)<br />
</li>
<li><strong>Headquarters</strong>: Mumbai, India</li>
</ul>
<hr />
</div>
<div id="tailwinds-growth-drivers" class="section level6">
<h6>üìà <strong>Tailwinds &amp; Growth Drivers</strong></h6>
<div id="strong-revenue-and-profit-growth" class="section level9">
<p class="heading">1. <strong>Strong Revenue and Profit Growth</strong></p>
<ul>
<li>Q2 FY26 (Ended Sep 2025):
<ul>
<li><strong>Revenue</strong>: ‚Çπ3,249 crore (+3.7% YoY vs.¬†‚Çπ3,134 crore)<br />
</li>
<li><strong>Profit After Tax (PAT)</strong>: ‚Çπ88.5 crore (+7.5% YoY)<br />
</li>
</ul></li>
<li>H1 FY26 (6 months):
<ul>
<li>PAT of <strong>‚Çπ154.7 crore</strong> vs.¬†<strong>‚Çπ99.1 crore</strong> in same period last year (up <strong>+56%</strong>, partly due to exceptional items in prior period).<br />
</li>
</ul></li>
<li><em>Press release claims sales grew 3% and PAT up 8%</em>, confirming resilient fundamentals.</li>
</ul>
</div>
<div id="robust-cash-flow-generation" class="section level9">
<p class="heading">2. <strong>Robust Cash Flow Generation</strong></p>
<ul>
<li><strong>Operating Cash Flow (H1 FY26)</strong>: ‚Çπ17,223 lakh<br />
</li>
<li>Strong inflows support business reinvestments, dividends, and strategic initiatives<br />
</li>
<li>High cash &amp; equivalents: ‚Çπ27,930 lakh (vs.¬†‚Çπ18,208 lakh at prior year-end)</li>
</ul>
</div>
<div id="effective-cost-management-margin-expansion" class="section level9">
<p class="heading">3. <strong>Effective Cost Management &amp; Margin Expansion</strong></p>
<ul>
<li>Despite rising input costs, <strong>Net Profit Margin improved</strong> from <strong>~3.2% in 6-months Sep 2024</strong> to <strong>~23.0% in Sep 2025</strong>, driven largely by:
<ul>
<li><strong>Discontinuation of Injection Manufacturing (Goa plant)</strong> and asset sale (‚Çπ790 lakh)<br />
</li>
<li>Impairment of associated assets (one-time), reducing future drag on margins</li>
</ul></li>
</ul>
</div>
<div id="product-innovation-driving-demand" class="section level9">
<p class="heading">4. <strong>Product Innovation Driving Demand</strong></p>
<ul>
<li>Launches like <strong>Livogen Iron Gummies</strong> (consumer-friendly iron supplement) and <strong>Neurobion Nerve Pain Relief Cream</strong> are contributing to:
<ul>
<li>New consumer acquisition<br />
</li>
<li>Product mix upgrade<br />
</li>
<li>Brand relevance in self-care &amp; wellness trends</li>
</ul></li>
</ul>
</div>
<div id="effective-leadership-transition-governance" class="section level9">
<p class="heading">5. <strong>Effective Leadership Transition &amp; Governance</strong></p>
<ul>
<li>Successful shareholder approval (via postal ballot) of <strong>Mr.¬†Shashank Srowthy as Executive Director</strong> (Nov 2025)
<ul>
<li>Over <strong>99.6% voting support</strong> indicates investor confidence<br />
</li>
<li>Reflects smooth governance and leadership continuity under MD <strong>Milind Thatte</strong></li>
</ul></li>
</ul>
</div>
<div id="favorable-market-trends" class="section level9">
<p class="heading">6. <strong>Favorable Market Trends</strong></p>
<ul>
<li>Rising health consciousness post-pandemic<br />
</li>
<li>Increasing OTC (over-the-counter) and self-medication behavior in India<br />
</li>
<li>Growing focus on preventive healthcare drives demand for VMS segment</li>
</ul>
</div>
<div id="strategic-supply-chain-and-go-to-market-efficiency" class="section level9">
<p class="heading">7. <strong>Strategic Supply Chain and Go-to-Market Efficiency</strong></p>
<ul>
<li>Management commentary highlights improvements in:
<ul>
<li>Supply chain resilience<br />
</li>
<li>Consumer communication (especially on Evion and Seven Seas)<br />
</li>
<li>Sales &amp; distribution effectiveness</li>
</ul></li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level6">
<h6>‚ö†Ô∏è <strong>Headwinds &amp; Challenges</strong></h6>
<div id="high-base-effect-marginal-decline-in-revenue-vs.-previous-quarter" class="section level9">
<p class="heading">1. <strong>High Base Effect &amp; Marginal Decline in Revenue vs.¬†Previous Quarter</strong></p>
<ul>
<li>Q2 revenue (<strong>‚Çπ3,249 crore</strong>) down from Q1‚Äôs <strong>‚Çπ3,387 crore</strong>, indicating possible seasonality or softer demand<br />
</li>
<li>Sequential decline (-4%) may reflect:
<ul>
<li>Inventory destocking by distributors<br />
</li>
<li>Elevated Q1 purchases ahead of monsoon/heavy sales season</li>
</ul></li>
</ul>
</div>
<div id="high-dependency-on-few-legacy-brands" class="section level9">
<p class="heading">2. <strong>High Dependency on Few Legacy Brands</strong></p>
<ul>
<li>Majority of sales come from legacy brands: <strong>Neurobion, Evion, Livogen</strong>, etc.<br />
</li>
<li>Limited diversification into newer therapeutic areas or higher-margin Rx segments<br />
</li>
<li>Risk of brand fatigue without continuous R&amp;D/product innovation</li>
</ul>
</div>
<div id="weak-segment-disclosure" class="section level9">
<p class="heading">3. <strong>Weak Segment Disclosure</strong></p>
<ul>
<li>Declared ‚ÄúPharmaceuticals‚Äù as single segment under Ind AS 108<br />
</li>
<li>No segmental income or geographic breakdown limits transparency<br />
</li>
<li>Investors cannot assess performance of individual brands or markets</li>
</ul>
</div>
<div id="one-time-boost-in-profitability" class="section level9">
<p class="heading">4. <strong>One-time Boost in Profitability</strong></p>
<ul>
<li>YoY H1 PAT growth (56%) is inflated due to comparison with a period that included <strong>‚Çπ201.9 crore exceptional loss</strong> (asset write-offs in FY24)<br />
</li>
<li>Underlying operational improvement may be less dramatic<br />
</li>
<li>Risk of margin normalization if cost control eases</li>
</ul>
</div>
<div id="no-subsidiaries-joint-ventures-or-associate-companies" class="section level9">
<p class="heading">5. <strong>No Subsidiaries, Joint Ventures, or Associate Companies</strong></p>
<ul>
<li>Reduces diversification and external growth potential<br />
</li>
<li>Growth must be organic, which can limit scalability during high opportunity periods</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects-strategic-outlook" class="section level6">
<h6>üîÆ <strong>Growth Prospects &amp; Strategic Outlook</strong></h6>
<table>
<colgroup>
<col width="31%" />
<col width="68%" />
</colgroup>
<thead>
<tr class="header">
<th>Area</th>
<th>Opportunity</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Product Innovation</strong></td>
<td>Expansion into gummies, creams, and women‚Äôs health can attract younger demographics and increase market share</td>
</tr>
<tr class="even">
<td><strong>Distribution Reach</strong></td>
<td>Rural and semi-urban penetration in India remains underexploited</td>
</tr>
<tr class="odd">
<td><strong>Digital &amp; E-commerce</strong></td>
<td>Growing D2C and pharma e-commerce channels (e.g., PharmEasy, Apollo 24/7) offer low-cost access to consumers</td>
</tr>
<tr class="even">
<td><strong>Export Potential</strong></td>
<td>P&amp;G global network offers possible platform for international expansion of Indian-made VMS products</td>
</tr>
<tr class="odd">
<td><strong>Consumer Communication</strong></td>
<td>Strong campaigns on Evion, Seven Seas can reinforce brand trust and drive repeat purchases</td>
</tr>
</tbody>
</table>
<p>üìä <em>Guidance</em>: While not explicitly given, management‚Äôs tone is <strong>bullish on sustained momentum</strong>, citing balanced top-line and bottom-line growth for two quarters in a row.</p>
<hr />
</div>
<div id="key-risks-red-flags" class="section level6">
<h6>‚ö†Ô∏è <strong>Key Risks &amp; Red Flags</strong></h6>
<table>
<colgroup>
<col width="50%" />
<col width="50%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory &amp; Compliance Risk</strong></td>
<td>Pharma sector faces tightening controls on advertising claims, labeling, and pricing in India (e.g., DCA scrutiny)</td>
</tr>
<tr class="even">
<td><strong>Raw Material Price Volatility</strong></td>
<td>Cost of materials consumed increased from ‚Çπ4,817L (Q2 FY24) to ‚Çπ7,813L (Q2 FY25). Margin pressure possible if input costs rise further</td>
</tr>
<tr class="odd">
<td><strong>Concentration Risk</strong></td>
<td>High reliance on the VMS category; any health advisory against supplements could impact multiple brands simultaneously</td>
</tr>
<tr class="even">
<td><strong>Governance Risk (Minor)</strong></td>
<td>Limited institutional voting data transparency in postal ballot ‚Äî only ~0.53% of total shareholders cast e-votes (430 out of 51,591), though vote was highly affirmative</td>
</tr>
<tr class="odd">
<td><strong>Change in Financial Year</strong></td>
<td>Makes YoY comparisons complex; current H1 2025 includes prior audited + unaudited figures combined</td>
</tr>
<tr class="even">
<td><strong>Dividend Payout Pressure</strong></td>
<td>H1 FY26 dividends paid: ‚Çπ747 crore (vs.¬†net profit of ‚Çπ154.7 crore), suggesting high payout ratio. May limit retained earnings for growth</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="financial-highlights-h1-fy26-aprsep-2025" class="section level6">
<h6>üìä <strong>Financial Highlights (H1 FY26: Apr‚ÄìSep 2025)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>H1 FY26 (‚Çπ in lakhs)</th>
<th>YoY Change</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Revenue from Operations</td>
<td>66,366</td>
<td>+11.1%* (*vs.¬†adjusted prior)</td>
</tr>
<tr class="even">
<td>Other Income</td>
<td>898</td>
<td>+65.7%</td>
</tr>
<tr class="odd">
<td>Total Income</td>
<td>67,264</td>
<td>+11.6%</td>
</tr>
<tr class="even">
<td>Total Expenses</td>
<td>46,481</td>
<td>+3.7%</td>
</tr>
<tr class="odd">
<td>Profit Before Tax</td>
<td>20,783</td>
<td>+54.1%</td>
</tr>
<tr class="even">
<td>Net Profit (after tax)</td>
<td>15,472</td>
<td>+56.2%</td>
</tr>
<tr class="odd">
<td>EPS (Basic)</td>
<td>‚Çπ93.21</td>
<td>‚Äî</td>
</tr>
<tr class="even">
<td>Cash &amp; Equivalents</td>
<td>27,930</td>
<td>‚ñ≤ from 18,208 (Mar 2025)</td>
</tr>
<tr class="odd">
<td>Total Equity</td>
<td>61,973</td>
<td>‚ñ≤ from 53,696 (Mar 2025)</td>
</tr>
</tbody>
</table>
<p>_*Note: Prior year figures adjusted due to FY change (Sep 2024 = nine months + first quarter of new FY combined)_</p>
<hr />
</div>
<div id="conclusion-investment-call-summary" class="section level6">
<h6>‚úÖ <strong>Conclusion: Investment Call Summary</strong></h6>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th>Parameter</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Business Health</strong></td>
<td>‚úÖ Strong ‚Äì improving profitability &amp; cash flows</td>
</tr>
<tr class="even">
<td><strong>Growth Trajectory</strong></td>
<td>‚úÖ Stable ‚Äì innovation-led, double-digit income growth</td>
</tr>
<tr class="odd">
<td><strong>Management Quality</strong></td>
<td>‚úÖ High ‚Äì transparent disclosures, strong governance</td>
</tr>
<tr class="even">
<td><strong>Valuation (Not given, but implied)</strong></td>
<td>üî∂ Watch for P/E expansion based on earnings momentum</td>
</tr>
<tr class="odd">
<td><strong>Overall Outlook</strong></td>
<td><strong>POSITIVELY BULLISH</strong> for medium term</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="investor-recommendation-summary" class="section level6">
<h6>üß© <strong>Investor Recommendation (Summary)</strong></h6>
<blockquote>
<p><strong>Hold / Buy (Accumulate on Dips)</strong><br />
PGHL presents a <strong>high-quality play on India‚Äôs wellness and preventive health wave</strong>. The company is executing well, innovating sustainably, and managing margins effectively. While short-term volatility in revenue and one-time factors exist, long-term prospects are bright.</p>
<p><strong>Monitor</strong>: - Sustainability of new product traction<br />
- Input cost pressures<br />
- Regulatory developments in OTC space<br />
- Future capital allocation (dividend vs.¬†reinvestment)</p>
</blockquote>
<hr />
</div>
<div id="appendices-key-references-from-documents" class="section level6">
<h6>üìé Appendices (Key References from Documents)</h6>
<ul>
<li><strong>Unaudited Results Dated Nov 5, 2025</strong> ‚Äì Core financials, auditor‚Äôs limited review (unmodified opinion)<br />
</li>
<li><strong>Postal Ballot Results (Nov 17, 2025)</strong> ‚Äì Governance transparency, leadership addition<br />
</li>
<li><strong>Change in FY (Effective FY26)</strong> ‚Äì Aligns with calendar; improves comparability going forward<br />
</li>
<li><strong>Press Release</strong> ‚Äì Confirms narrative of innovation-driven growth</li>
</ul>
<hr />
<p><em>Prepared using disclosed public documents as of November 17, 2025.</em><br />
<em>Not a formal investment advice; conduct independent due diligence before investing.</em></p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
